Document Detail


Olanzapine-induced hyperglycaemic coma and neuroleptic malignant syndrome: case report and review of literature.
MedLine Citation:
PMID:  18801826     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Although the relationship between antipsychotic medication, particularly second-generation antipsychotics (SGAs), and metabolic disturbance is increasingly accepted, there is an important, but little recognised, potential interaction between this and the other important serious adverse effect of neuroleptic malignant syndrome (NMS). We report a case of a 35-year old female who developed new onset type II diabetes mellitus with hyperosmolar hyperglycaemic coma and acute renal failure following treatment with a SGA for a first manic episode. The history is strongly suggestive of concurrent NMS. This case raises important questions about non-ketotic, hyperosmolar diabetic coma with antipsychotics, the possible association between hyperglycaemia and hyperthermia, and the direction of causality in this, the recognition of either syndrome when they co-exist and management issues in such patients. These questions are considered in the context of currently available literature.
Authors:
N Ahuja; N Palanichamy; P Mackin; Aj Lloyd
Related Documents :
11585716 - Neuropsychological correlates of schizophrenic syndromes in patients treated with atypi...
18411156 - Measurement of parathyroid hormone-related peptide in the circulation.
1967846 - Neuroleptic-induced catatonia: neuroleptic malignant syndrome?
10778776 - Primary carcinoid tumor of the ovary: report of an unusual case.
10517476 - Bartsocas-papas syndrome with fusion of the lips and posterior fusion defects of the th...
10798366 - Linkage of recessive robinow syndrome to a 4 cm interval on chromosome 9q22.
Publication Detail:
Type:  Case Reports; Journal Article; Research Support, Non-U.S. Gov't     Date:  2008-09-18
Journal Detail:
Title:  Journal of psychopharmacology (Oxford, England)     Volume:  24     ISSN:  1461-7285     ISO Abbreviation:  J. Psychopharmacol. (Oxford)     Publication Date:  2010 Jan 
Date Detail:
Created Date:  2010-02-04     Completed Date:  2010-04-15     Revised Date:  2011-07-21    
Medline Journal Info:
Nlm Unique ID:  8907828     Medline TA:  J Psychopharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  125-30     Citation Subset:  IM    
Affiliation:
Wallsend Community Mental Health Team, Sir GB Hunter Hospital, Wallsend, Tyne and Wear, UK. niraj.ahuja@ncl.ac.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Kidney Injury / chemically induced
Adult
Antipsychotic Agents / adverse effects*,  therapeutic use
Benzodiazepines / adverse effects*,  therapeutic use
Bipolar Disorder / drug therapy
Diabetes Mellitus, Type 2 / chemically induced
Female
Humans
Hyperglycemic Hyperosmolar Nonketotic Coma / chemically induced*
Neuroleptic Malignant Syndrome / etiology*
Chemical
Reg. No./Substance:
0/Antipsychotic Agents; 12794-10-4/Benzodiazepines; 132539-06-1/olanzapine
Comments/Corrections
Comment In:
J Psychopharmacol. 2011 Jun;25(6):850   [PMID:  20488833 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in health...
Next Document:  Inhibition of THC-induced effects on the central nervous system and heart rate by a novel CB1 recept...